CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES ›› 2023, Vol. 41 ›› Issue (4): 510-515.doi: 10.12140/j.issn.1000-7423.2023.04.020

• SHORT COMMUNICATIONS • Previous Articles     Next Articles

Mechanism of a Chinese patent medicine in the treatment of liver fibrosis caused by infection of Clonorchis sinensis based on network pharmacology

LI Tianxing1(), ZHANG Jiaming1, XU Chenxi1, WANG Zige1, GUO Jingjie1, LI Shan2,*()   

  1. 1 Clinical Medicine, The Fifth Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou 450042, China
    2 Department of Pathology and Pathophysiology, School of Medicine, Henan University of Chinese Medicine, Zhengzhou 450046, China
  • Received:2022-10-12 Revised:2023-01-22 Online:2023-08-30 Published:2023-09-06
  • Contact: *E-mail: 185777388@qq.com
  • Supported by:
    Training Program for Young scholars in Universities of Henan Province(2021GGJS084);Important Scientific Research Project of Universities in Henan Province(21B310003);Nursery Project of Scientific Research in Henan University of Chinese Medicine(MP2021-94)

Abstract:

To explore the pharmacological efficacy and molecular mechanism of FufangBiejiaRuanganPian (FBRP, a Chinese patent medicine) in the treatment of liver fibrosis caused by Clonorchis sinensis infection, we obtained the active compounds from the 11 Chinese ingredients of FBRP and their potential targets as well as clonorchiasis and liver fibrosis related targets through the TCMSP, BATMAN-TCM, Swiss and GeneCards databases. The intersection targets were screened for the construction of protein-protein interaction and drug-component-target-disease networks as well as analysis of GO and KEGG enrichments. The core targets were used for molecular docking with their corresponding compounds. The results showed 17 targets from the intersection of FBRP active components, clonorchiasis and liver fibrosis. The top 5 targets from degree ranking were cysteinyl aspartate-specific proteinase-3 (CASP3), cysteine x chemokine ligand 8 (CXCL8), tumor necrosis factor (TNF), proto-oncogene tyrosine-protein kinase src (SRC), and interleukin 10 (IL-10). The compound that showed the lowest binding energy for molecular docking with these 5 targets were respectively baicalein, wogonin, 24-ethylcholest-4-en-3-one, 24-ethylcholest-4-en-3-one, and 24-ethylcholest-4-en-3-one. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment and Gene Ontology (GO) function analysis suggested that FBRP could regulate cell apoptosis and proliferation, reduce the inflammatory response and oxidative stress injury, and inhibit the expression of pro-fibrotic factors. It could play a role in the treatment of liver fibrosis caused by infection of Clonorchis sinensis through the phosphatidylinositol 3 kinase-protein kinase B (PI3K-Akt), mitogen-activated protein kinase (MAPK) and janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways.

Key words: Clonorchiasis, FufangBiejiaRuanganPian, Liver fibrosis, Network pharmacology

CLC Number: